Bio Gene Technology Stock Current Valuation
| BGT Stock | 0.04 0 4.55% |
Valuation analysis of Bio Gene Technology helps investors to measure Bio Gene's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Bio Gene's Cash is comparatively stable compared to the past year. Cash And Short Term Investments is likely to gain to about 4.1 M in 2024, despite the fact that Other Cashflows From Financing Activities is likely to grow to (5.4 K). Fundamental drivers impacting Bio Gene's valuation include:
Price Book 3.03 | Enterprise Value 6.2 M | Enterprise Value Ebitda (2.71) | Price Sales 483.619 | Enterprise Value Revenue 10.7329 |
Overvalued
Today
Please note that Bio Gene's price fluctuation is out of control at this time. Calculation of the real value of Bio Gene Technology is based on 3 months time horizon. Increasing Bio Gene's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Bio Gene's intrinsic value may or may not be the same as its current market price of 0.04, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.042 | Real 0.037 | Hype 0.04 | Naive 0.0483 |
The intrinsic value of Bio Gene's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bio Gene's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bio Gene Technology helps investors to forecast how Bio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bio Gene more accurately as focusing exclusively on Bio Gene's fundamentals will not take into account other important factors: Bio Gene Technology Company Current Valuation Analysis
Bio Gene's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Bio Gene Current Valuation | 6.25 M |
Most of Bio Gene's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Gene Technology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Bio Gene Technology has a Current Valuation of 6.25 M. This is 99.96% lower than that of the Chemicals sector and 99.87% lower than that of the Materials industry. The current valuation for all Australia stocks is 99.96% higher than that of the company.
Bio Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Gene's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Gene could also be used in its relative valuation, which is a method of valuing Bio Gene by comparing valuation metrics of similar companies.Bio Gene is currently under evaluation in current valuation category among its peers.
Bio Fundamentals
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 6.25 M | ||||
| Shares Outstanding | 201.36 M | ||||
| Shares Owned By Insiders | 43.33 % | ||||
| Price To Book | 3.03 X | ||||
| Price To Sales | 483.62 X | ||||
| Revenue | 18.32 K | ||||
| Gross Profit | 222.1 K | ||||
| EBITDA | (2.97 M) | ||||
| Net Income | (2.41 M) | ||||
| Total Debt | 368.45 K | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (2.75 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 0.37 | ||||
| Beta | 0.71 | ||||
| Market Capitalization | 8.86 M | ||||
| Total Asset | 3.16 M | ||||
| Retained Earnings | (19.64 M) | ||||
| Working Capital | 2.59 M | ||||
| Net Asset | 3.16 M |
About Bio Gene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Gene Technology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Gene Technology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bio Stock Analysis
When running Bio Gene's price analysis, check to measure Bio Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Gene is operating at the current time. Most of Bio Gene's value examination focuses on studying past and present price action to predict the probability of Bio Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Gene's price. Additionally, you may evaluate how the addition of Bio Gene to your portfolios can decrease your overall portfolio volatility.